dolutegravir + tenofovir disoproxil fumarate

**Dolutegravir + tenofovir disoproxil fumarate** is a two-drug combination used primarily as antiretroviral therapy for the treatment of HIV-1 infection. Its components work via different mechanisms: **dolutegravir** is an integrase strand transfer inhibitor (INSTI) that blocks the action of HIV integrase, thereby preventing integration of viral DNA into the host genome, while **tenofovir disoproxil fumarate** is a nucleotide reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase, resulting in chain termination during viral DNA synthesis. This combination is often part of a triple therapy regimen, most commonly with lamivudine, but dolutegravir + tenofovir disoproxil fumarate may be used in certain dual therapy regimens as an alternative or due to contraindications to other agents. Both components are small molecule drugs intended for oral administration in adults and adolescents with HIV-1. The combination provides a potent, once-daily regimen for a wide range of patients, including those co-infected with tuberculosis if dose adjustments are made to dolutegravir.

Other names

dolutegravir and tenofovir disoproxil fumarateDTG + TDF